NEW YORK (GenomeWeb News) – Molecular diagnostics firm Cepheid today said that it has received the CE Mark for its test that rapidly identifies the vanA and/or vanB genes, which are most commonly associated with vancomycin-resistant Enterococci.
 
The Sunnyvale, Calif.-based firm also said that it has launched the Xpert vanA/vanB test, which provides results in 45 minutes and runs on the company’s GeneXpert System. It is the first test developed and manufactured by Cepheid’s Swedish subsidiary, Cepheid AB.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.